We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ancient Viruses Built from Computer Models May Improve Gene Therapy Delivery

By LabMedica International staff writers
Posted on 12 Aug 2015
An advanced computer modeling strategy was used to design ancient forms of adeno-associated viruses (AAVs), which were then synthesized in the laboratory for use as potential delivery vectors for gene therapy.

AAV vectors have emerged as a gene-delivery platform with demonstrated safety and efficacy in a handful of clinical trials for monogenic disorders. However, limitations of the current generation of vectors—including rejection by the patient's immune system—often prevent broader application of AAV gene therapy. Efforts to engineer AAV vectors have been hampered by a limited understanding of the structure-function relationship of the complex multimeric icosahedral architecture of the particle.

Image: Artist\'s conception of an adeno-associated viral capsid in formation by ancestral sequence reconstruction (Photo courtesy of Dr. Eric Zinn, Harvard University Medical School).
Image: Artist\'s conception of an adeno-associated viral capsid in formation by ancestral sequence reconstruction (Photo courtesy of Dr. Eric Zinn, Harvard University Medical School).

To bypass these limitations investigators at Harvard University Medical School (Boston, MA, USA) built computer models of the AAC viral capsid using ancestral sequence reconstruction from inferred evolutionary intermediates. Computer model-derived sequences were synthesized in the laboratory and characterized for biological properties relevant to clinical applications.

Results published in the July 30, 2015, online edition of the journal Cell Reports described the generation of nine functional putative ancestral AAVs and the identification of Anc80, the predicted ancestor of the widely studied AAV serotypes 1, 2, 8, and 9, as a highly potent in vivo gene therapy vector for targeting liver, muscle, and retina.

"The vectors developed and characterized in this study demonstrate unique and potent biology that justify their consideration for gene therapy applications," said senior author Dr. Luk H. Vandenberghe, professor of ophthalmology at Harvard University Medical School. "We believe our findings will teach us how complex biological structures, such as AAVs (adeno-associated viruses), are built. From this knowledge, we hope to design next-generation viruses for use as vectors in gene therapy."

Related Links:

Harvard University Medical School



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries